Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Bayhill Therapeutics

Request full access

Bayhill Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for

Portola Valley, United StatesFounded 2000Biotech & Life Sciences

About Bayhill Therapeutics

Bayhill Therapeutics, operating initially as Tolerion Inc., was a clinical-stage biopharmaceutical firm established in 2000 by Lawrence Steinman and Hideki Garren. The company focused on developing treatments for autoimmune diseases by leveraging its proprietary BHT-DNA therapeutic platform. This platform was designed to re-educate the immune system and restore its tolerance to self-antigens, selectively eliminating harmful immune responses without impacting the rest of the immune system. The business model centered on advancing its drug candidates through clinical trials and forming strategic partnerships with larger pharmaceutical companies for further development and commercialization.

The company's pipeline included several promising candidates. BHT-3009 was developed for multiple sclerosis and completed a Phase II trial. Another key asset, BHT-3021, targeted type 1 diabetes. This DNA-based immunotherapy, which encodes for human proinsulin, aimed to halt the autoimmune damage to the pancreas. A third candidate, BHT-3034, was developed for myasthenia gravis and received clearance for a Phase I/II clinical study.

Throughout its operation, Bayhill Therapeutics secured significant financing, raising a total of $138 million over six funding rounds from investors such as TriplePoint Capital, USVP, Morgenthaler Ventures, and Lilly Ventures. A major milestone was the exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development and commercialization of BHT-3021. This deal included an upfront payment of $25 million and potential milestone payments exceeding $325 million. Despite its clinical progress and successful fundraising, the company attempted an IPO in 2008 but had to withdraw due to unfavorable market conditions. Bayhill Therapeutics was ultimately dissolved in 2012.

Source: Dealroom company data

At a glance

Status
Closed
Employees
16
Open positions
None listed
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Jul 2009 $10M $40M Undisclosed —
SERIES BEquity / VC May 2005 $35M $142M Latterell Venture Partners · Lilly Ventures · U.S. Venture Partners · Pappas Capital —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Bayhill Therapeutics website traffic

Latest recorded traffic for Bayhill Therapeutics is 0 monthly website visits. Bayhill Therapeutics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Bayhill Therapeutics in the Portola Valley ecosystem

Live from Dealroom

The Bayhill Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

  • Morgenthaler Ventures
  • CMEA Ventures
  • U.S. Venture Partners
  • The Vertical Group
  • Latterell Venture Partners
  • Lilly Ventures
  • DeNovo Ventures
  • Pappas Capital
  • Pac-Link
  • IQVIA
  • Montreux Equity Partners

Other known investors1 additional known investor

  • University of Miami
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Portola Valley HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Bayhill Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bayhill Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.